Archive for the ‘Pharmaceuticals India’ Category

India will continue to allow 100% Fdi in Greenfield Pharma

Comments Off | 10-12-2011

PM chaired a high level meeting to discuss the FDI policy in drugs and pharmaceutical sector. The meeting was attended by Finance Minister, Sh Pranab Mukherji, Health Minister Sh Ghulam Nabi Azad, Commerce, Industry and Textile Minister Sh Anand Sharma, Pharmaceutical and Chemical Minister Sh MK Alagiri, Deputy Chairman Planning Commission Dr Montek Singh Ahulwalia,

Tags: , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Par Pharmaceutical Companies to acquire India’s privately-held Edict Pharmaceuticals

Comments Off | 05-25-2011

Par Pharmaceutical Companies, Inc. (PRX) announced Tuesday that it entered into a definitive agreement to acquire privately-held Edict Pharmaceuticals, an India-based developer and manufacturer of generic pharmaceuticals, for up to $37.6 million in cash and Par’s repayment of certain additional pre-close indebtedness. The transaction is expected to be accretive in 2013.
Edict Pharmaceuticals is a Chennai,

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

GlaxoSmithKline Biologicals looking to acquire Biological E Limited’s vaccine division

Comments Off | 04-23-2011

The Economic Times of India Wednesday reported that GlaxoSmithKline Biologicals is keen on acquiring India’s Biological E Limited’s vaccine division. GlaxoSmithKline Biologicals is a Belgium based division of global drug giant Glaxo. The Hyderabad based Biological E Limited’s vaccine division produces and markets a range of pediatric and adult vaccines.
Biological E Limited is a biopharmaceutical

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Pharmaceutical manufacturer SOHM Inc. to acquire an Indian Dermatology Company

Comments Off | 04-8-2011

SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced Thursday that it has signed a Letter Of Intent (LOI) to acquire a high-growth dermatology company based in India.
Upon the successful close of the acquisition, which is expected in the second quarter of fiscal year 2011, the

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Publicis Groupe picks up majority stake in leading Mumbai healthcare advertising agency

Comments Off | 03-24-2011

Publicis Groupe is to acquire a majority stake in Watermelon Healthcare Communications Private Limited, a leading healthcare advertising agency in Mumbai, India. Post the stake acquisition, Watermelon will become part of Publicis Healthcare Communications Group (PHCG) and will be renamed Publicis Life Brands Watermelon. This transaction is subject to customary local closing conditions.
Watermelon is a

Tags: , , , , , , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Cx Partners invests Rs 188 Crore in medical diagnostics firm Thyrocare Technologies Ltd

Comments Off | 12-29-2010

Cx Partners reported it had invested around Rs 188 crore in Thyrocare Technologies for the acquisition of a 30 per cent stake. Cx Partners, the private equity firm, will acquire the stake in the medical diagnostics firm, valuing Thyrocare Technologies Ltd at Rs 627 Crore. According to the firm, the funds to be accrued from

Tags: , , , , , , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Jordanian firm Hikma Pharmaceuticals to buy 30 per cent stake in India’s API manufacturer Unimark Remedies

Comments Off | 12-25-2010

Jordanian firm Hikma Pharmaceuticals is to buy 30 per cent stake in Indian API manufacturer Unimark Remedies Ltd. Unimark Remedies Ltd is based in Mumbai, and the deal is pegged at about Rs 150 Crore. That subsequently places the value of the Indian firm at about Rs 500 Crore. Hikma is a branded generic company

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Aventis Pharma Ltd exits joint venture vaccine manufacturer Chiron Behring Vaccines Pvt Ltd

Comments Off | 12-14-2010

Drug manufacturer, Aventis Pharma Ltd’s subsidiary Sanofi-Aventis is exiting its joint venture vaccine making firm Chiron Behring Vaccines Pvt Ltd (CVBPL), by selling its 49% stake to its nominee partner Novartis Pharma AG for $22.399 million, around Rs.101.1 Cr.
Aventis Pharma will sell its stake to Novartis Pharma AG, a nominee of joint venture partner Novartis

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

Abbott India board of directors approves proposal to merge the company with Solvay Pharma

Comments Off | 11-28-2010

India based drug firm Abbot India announced that its board of directors had approved a proposal seeking to merge the firm with Solvay Pharma. The proposal is a 2:3 share swap ratio. In a filling to the Bombay Stock Exchange, Abbot reiterated the swap merger would be under 2:3 ratio, and every two share(s) of

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

US based Cambrex Corporation buys 51 per cent stake in Hyderabad based Indian pharmaceuticals firm Zenara Pharma

Comments Off | 11-4-2010

US firm Cambrex Corporation Wednesday announced it had bought a 51 per cent stake in India pharmaceuticals firm Zenara Pharma. Zenara Pharma is a Hyderabad based pharmaceutical company focused on the formulation of final dosage form products. The acquired entity will now be renamed Cambrex Zenara and the investment is expected to position Cambrex as

Tags: , , , , , , , , ,
Posted in FDI news India, General, Pharmaceuticals India | Read More

© Invest in India | Investinindia.com